EA201991188A1 - NEW GLUTAMINYL CYCLES INHIBITORS AND THEIR APPLICATION FOR TREATMENT OF VARIOUS DISEASES - Google Patents

NEW GLUTAMINYL CYCLES INHIBITORS AND THEIR APPLICATION FOR TREATMENT OF VARIOUS DISEASES

Info

Publication number
EA201991188A1
EA201991188A1 EA201991188A EA201991188A EA201991188A1 EA 201991188 A1 EA201991188 A1 EA 201991188A1 EA 201991188 A EA201991188 A EA 201991188A EA 201991188 A EA201991188 A EA 201991188A EA 201991188 A1 EA201991188 A1 EA 201991188A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
treatment
group
diseases
glutaminyl
Prior art date
Application number
EA201991188A
Other languages
Russian (ru)
Inventor
Владимир Евгеньевич НЕБОЛЬСИН
Татьяна Александровна КРОМОВА
Анастасия Владимировна РЫДЛОВСКАЯ
Original Assignee
Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Фарминтерпрайсез" filed Critical Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Priority claimed from PCT/RU2018/050058 external-priority patent/WO2018217139A1/en
Publication of EA201991188A1 publication Critical patent/EA201991188A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02005—Glutaminyl-peptide cyclotransferase (2.3.2.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Изобретение относится к химии органических соединений, фармакологии и медицине и касается терапии заболеваний, связанных с аберрантной активностью клеток иммунной системы, в частности для терапии заболеваний легких, дыхательных путей и брюшной полости, лучевой болезни и болевого синдрома, а также других заболеваний посредством применения соединений формулы (A)в которой Rпредставляет собой группу -C(O)-R-C(O)- или -R-C(O)-, где Rпредставляет собой группу -(CH)-, необязательно замещенную одним или двумя C-C-алкилами, или фенил, n представляет собой целое число от 0 до 4; причем соединения выбраны из группы, состоящей из группы соединений, как представлено в описании. Данные соединения, а также их фармацевтически приемлемые соли обладают высокой эффективностью в ингибировании глутаминилциклазы, вовлеченной, в частности, в процессы пост-трансляционной модификации хемокинов и хемотаксиса моноцитов, макрофагов и других клеток иммунной системы. Данное изобретение также относится к фармацевтическим композициям, содержащим терапевтически эффективное количество соединений формулы (A), определенной выше.The invention relates to chemistry of organic compounds, pharmacology and medicine and concerns the treatment of diseases associated with aberrant activity of cells of the immune system, in particular for the treatment of diseases of the lungs, respiratory tract and abdominal cavity, radiation sickness and pain syndrome, as well as other diseases through the use of compounds of the formula (A) in which R is a -C(O)-RC(O)- or -RC(O)- group, where R is a -(CH)- group optionally substituted with one or two CC-alkyls, or phenyl, n is an integer from 0 to 4; moreover, the compounds are selected from the group consisting of the group of compounds, as presented in the description. These compounds, as well as their pharmaceutically acceptable salts, are highly effective in inhibiting glutaminyl cyclase, which is involved, in particular, in the processes of post-translational modification of chemokines and chemotaxis of monocytes, macrophages, and other cells of the immune system. This invention also relates to pharmaceutical compositions containing a therapeutically effective amount of compounds of formula (A) as defined above.

EA201991188A 2017-10-27 2018-05-24 NEW GLUTAMINYL CYCLES INHIBITORS AND THEIR APPLICATION FOR TREATMENT OF VARIOUS DISEASES EA201991188A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017137615A RU2662559C1 (en) 2017-10-27 2017-10-27 New inhibitor of glutaminyl cyclase and its use for treatment of lung and respiratory diseases
PCT/RU2018/050058 WO2018217139A1 (en) 2017-05-26 2018-05-24 Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases

Publications (1)

Publication Number Publication Date
EA201991188A1 true EA201991188A1 (en) 2020-04-15

Family

ID=62981762

Family Applications (4)

Application Number Title Priority Date Filing Date
EA202192894A EA202192894A1 (en) 2017-10-27 2018-05-24 NEW GLUTAMINE CYCLASE INHIBITORS AND THEIR APPLICATION FOR THE TREATMENT OF VARIOUS DISEASES
EA202192895A EA202192895A1 (en) 2017-10-27 2018-05-24 NEW GLUTAMINE CYCLASE INHIBITORS AND THEIR APPLICATION FOR THE TREATMENT OF VARIOUS DISEASES
EA202192892A EA202192892A2 (en) 2017-10-27 2018-05-24 NEW GLUTAMINE CYCLASE INHIBITORS AND THEIR APPLICATION FOR THE TREATMENT OF VARIOUS DISEASES
EA201991188A EA201991188A1 (en) 2017-10-27 2018-05-24 NEW GLUTAMINYL CYCLES INHIBITORS AND THEIR APPLICATION FOR TREATMENT OF VARIOUS DISEASES

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EA202192894A EA202192894A1 (en) 2017-10-27 2018-05-24 NEW GLUTAMINE CYCLASE INHIBITORS AND THEIR APPLICATION FOR THE TREATMENT OF VARIOUS DISEASES
EA202192895A EA202192895A1 (en) 2017-10-27 2018-05-24 NEW GLUTAMINE CYCLASE INHIBITORS AND THEIR APPLICATION FOR THE TREATMENT OF VARIOUS DISEASES
EA202192892A EA202192892A2 (en) 2017-10-27 2018-05-24 NEW GLUTAMINE CYCLASE INHIBITORS AND THEIR APPLICATION FOR THE TREATMENT OF VARIOUS DISEASES

Country Status (2)

Country Link
EA (4) EA202192894A1 (en)
RU (1) RU2662559C1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2697580C1 (en) * 2018-08-22 2019-08-15 Общество с ограниченной ответственностью "ЗЕТ Терапевтикс" New zinc complex, its preparation and application for therapy of human and animal diseases
RU2746692C1 (en) * 2020-04-14 2021-04-19 Общество С Ограниченной Ответственностью "Валента - Интеллект" Novel 2-(imidazol-4-yl)-ethanamide pentanedioic-1,5 acid compositions for treating and preventing viral diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962860B2 (en) * 2008-09-04 2015-02-24 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2012010470A (en) * 2010-03-10 2012-10-09 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5).
RU2665688C2 (en) * 2013-04-12 2018-09-04 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Dicarboxylic acid bisamide derivatives, their application, the pharmaceutical composition on their basis, methods for their production
RU2647438C2 (en) * 2015-05-27 2018-03-15 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Bisamide derivative of dicarboxylic acid as agent for stimulating tissue regeneration and recovery of diminished tissue function
DE102015011780A1 (en) * 2015-09-16 2017-03-16 Hochschule Anhalt New glutaminyl cyclase inhibitors

Also Published As

Publication number Publication date
RU2662559C1 (en) 2018-07-26
EA202192892A2 (en) 2022-02-28
EA202192894A1 (en) 2022-01-26
EA202192895A1 (en) 2022-01-26

Similar Documents

Publication Publication Date Title
CR20200488A (en) Peptide macrocycles against acinetobacter baumannii
MX2022010520A (en) Peptide macrocycles against acinetobacter baumannii.
MX2021006421A (en) Amino-acid anilides as small molecule modulators of il-17.
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX368504B (en) Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
UA107578C2 (en) COMBINED DIABETES THERAPY
CY1114215T1 (en) PHARMACEUTICAL SOLUTIONS FOR SOLID PRESSURE INHIBITORS
EA201270041A1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY LAKININIMODOM
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
EA201492010A1 (en) APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS
ATE307810T1 (en) IMIDAZOLE-2-CARBONIC ACID AMIDE DERIVATIVES AS RAF-KINASE INHIBITORS
DE602006017728D1 (en) CANCER TREATMENT BY AGENT AND 2-DEOXYGLUCOSE
JP2015532296A5 (en)
EA201291089A1 (en) METHOD FOR OBTAINING PHARMACEUTICAL PREPARATIONS INTENDED FOR ORAL ADMINISTRATION, CONTAINING ONE OR MORE ACTIVE INGREDIENTS AND CONTAINING COMPOSITIONS
EA200870469A1 (en) NEW, CONTAINING NIMESULIDE, PHARMACEUTICAL COMPOSITIONS WITH LOW DOSE, THEIR RECEPTION AND APPLICATION
RU2019141734A (en) THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND METHODS OF THEIR APPLICATION
MX2019006880A (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases.
EA201991188A1 (en) NEW GLUTAMINYL CYCLES INHIBITORS AND THEIR APPLICATION FOR TREATMENT OF VARIOUS DISEASES
CY1116274T1 (en) TRIAZOLI PRODUCT FOR USE IN TREATMENT OF NEUROPATHIC PAIN AND Fibromyalgia
TW200736203A (en) New pleuromutilin derivative and its use
EA202190064A1 (en) CYANOTRIAZOLE COMPOUNDS AND VARIANTS OF THEIR APPLICATION
SE0401655D0 (en) New compounds
TW200738599A (en) New pleuromutilin derivative and its use
SE0201837D0 (en) Chemical compounds